National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Dabigatran etexilate (Pradaxa®) for the Prevention of Stroke and Systemic Embolism in Adult Patients with Atrial Fibrillation

Pharmacoeconomic Evaluation

Commenced Completed Outcome
02/11/2010 03/06/2011 Reimbursement not Recommended

Dabigatran Etexilate (Pradaxa®) summary

03/10/2012

Following the NCPE pharmacoeconomic assessment (August 2011) the manufacturer reduced the price of dabigatran.  At this revised price we now consider dabigatran cost effective for this indication.